Repros Therapeutics: Winning the Battle but Losing the War?
Repros Therapeutics (NASDAQ:RPRX) is developing a drug named Androxal that targets raising testosterone in men. Repros is developing several other drugs for different purposes, however Androxal's prospects are driving much of the near-term expectations for Repros's valuation. Androxal is often projected to capture a significant share of the Testosterone replacement market if approved due to perceived advantages for Androxal related to preserving fertility and ease of use in comparison to testosterone replacement based on injections or other forms of supplemental Testosterone. The case for the likely approval of Androxal has been well-described by other SA authors and if anything, I believe the case for approval is even stronger...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|